Captor Therapeutics SA
WSE:CTX
Income Statement
Earnings Waterfall
Captor Therapeutics SA
Income Statement
Captor Therapeutics SA
| Dec-2020 | Mar-2021 | Jun-2021 | Sep-2021 | Dec-2021 | Mar-2022 | Jun-2022 | Sep-2022 | Dec-2022 | Mar-2023 | Jun-2023 | Sep-2023 | Dec-2023 | Mar-2024 | Jun-2024 | Sep-2024 | Dec-2024 | Mar-2025 | Jun-2025 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | ||||||||||||||||||||
| Interest Expense |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Revenue |
0
N/A
|
0
N/A
|
1
+243%
|
3
+86%
|
4
+47%
|
5
+15%
|
5
+4%
|
5
-3%
|
9
+98%
|
10
+6%
|
11
+12%
|
13
+16%
|
13
+5%
|
16
+22%
|
19
+15%
|
19
+4%
|
16
-18%
|
14
-12%
|
11
-20%
|
|
| Gross Profit | ||||||||||||||||||||
| Cost of Revenue |
0
|
0
|
0
|
(0)
|
(1)
|
(1)
|
(1)
|
(1)
|
(2)
|
(2)
|
(2)
|
(3)
|
(6)
|
(7)
|
(9)
|
(8)
|
(5)
|
(5)
|
(6)
|
|
| Gross Profit |
0
N/A
|
0
N/A
|
1
+243%
|
2
+53%
|
3
+46%
|
4
+10%
|
3
-4%
|
3
-6%
|
7
+119%
|
7
+5%
|
9
+22%
|
10
+5%
|
7
-28%
|
9
+27%
|
10
+10%
|
11
+14%
|
11
-4%
|
9
-12%
|
5
-43%
|
|
| Operating Income | ||||||||||||||||||||
| Operating Expenses |
(12)
|
(17)
|
(21)
|
(26)
|
(35)
|
(41)
|
(44)
|
(44)
|
(45)
|
(50)
|
(72)
|
(79)
|
(80)
|
(76)
|
(57)
|
(53)
|
(50)
|
(49)
|
(46)
|
|
| Selling, General & Administrative |
(10)
|
(13)
|
(17)
|
(23)
|
(29)
|
(33)
|
(36)
|
(39)
|
(23)
|
(19)
|
(16)
|
(11)
|
(21)
|
(19)
|
(19)
|
(16)
|
(14)
|
(15)
|
(14)
|
|
| Research & Development |
(17)
|
(8)
|
(7)
|
(12)
|
(17)
|
(19)
|
(22)
|
(21)
|
(38)
|
(45)
|
(59)
|
(69)
|
(61)
|
(58)
|
(46)
|
(41)
|
(38)
|
(40)
|
(42)
|
|
| Depreciation & Amortization |
(7)
|
(7)
|
(7)
|
(7)
|
(7)
|
(7)
|
(7)
|
(7)
|
(7)
|
(7)
|
(6)
|
(6)
|
(5)
|
(4)
|
(4)
|
(4)
|
(4)
|
(4)
|
(4)
|
|
| Other Operating Expenses |
21
|
12
|
10
|
17
|
19
|
18
|
21
|
23
|
23
|
21
|
9
|
6
|
7
|
6
|
11
|
9
|
6
|
10
|
14
|
|
| Operating Income |
(12)
N/A
|
(16)
-32%
|
(20)
-23%
|
(24)
-18%
|
(32)
-35%
|
(37)
-18%
|
(40)
-8%
|
(41)
-1%
|
(38)
+6%
|
(43)
-12%
|
(63)
-46%
|
(70)
-11%
|
(73)
-5%
|
(67)
+8%
|
(48)
+29%
|
(41)
+13%
|
(39)
+6%
|
(40)
-1%
|
(40)
-2%
|
|
| Pre-Tax Income | ||||||||||||||||||||
| Interest Income Expense |
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
1
|
3
|
4
|
5
|
4
|
3
|
2
|
1
|
1
|
1
|
0
|
1
|
|
| Non-Reccuring Items |
0
|
0
|
0
|
1
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Total Other Income |
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
0
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
0
|
|
| Pre-Tax Income |
(13)
N/A
|
(17)
-31%
|
(21)
-25%
|
(23)
-12%
|
(33)
-40%
|
(38)
-17%
|
(41)
-6%
|
(40)
+1%
|
(36)
+11%
|
(39)
-9%
|
(58)
-49%
|
(66)
-12%
|
(71)
-8%
|
(66)
+7%
|
(47)
+29%
|
(41)
+12%
|
(38)
+6%
|
(39)
-3%
|
(39)
+1%
|
|
| Net Income | ||||||||||||||||||||
| Tax Provision |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
(0)
|
(0)
|
(0)
|
(0)
|
0
|
0
|
0
|
0
|
0
|
|
| Income from Continuing Operations |
(13)
|
(17)
|
(21)
|
(23)
|
(33)
|
(38)
|
(41)
|
(40)
|
(36)
|
(39)
|
(58)
|
(66)
|
(71)
|
(66)
|
(47)
|
(41)
|
(38)
|
(39)
|
(39)
|
|
| Net Income (Common) |
(13)
N/A
|
(17)
-31%
|
(21)
-25%
|
(23)
-12%
|
(33)
-40%
|
(38)
-17%
|
(41)
-6%
|
(40)
+1%
|
(36)
+11%
|
(39)
-9%
|
(58)
-49%
|
(66)
-12%
|
(71)
-8%
|
(66)
+7%
|
(47)
+29%
|
(41)
+12%
|
(38)
+6%
|
(39)
-3%
|
(39)
+1%
|
|
| EPS (Diluted) |
-3.9
N/A
|
-5.1
-31%
|
-5.01
+2%
|
-5.63
-12%
|
-7.89
-40%
|
-11.73
-49%
|
-9.76
+17%
|
-9.66
+1%
|
-8.61
+11%
|
-9.3
-8%
|
-13.86
-49%
|
-15.19
-10%
|
-15.19
N/A
|
-14.16
+7%
|
-9.99
+29%
|
-8.75
+12%
|
-8.25
+6%
|
-7.18
+13%
|
-7.1
+1%
|
|